The government would make an advance payment of Rs 1,500 crore to Hyderabad-based vaccine maker Biological-E to reserve 300 million doses of the second India-developed vaccine from August-December 2021, the health ministry said on Thursday in a statement.
The Covid-19 vaccine of Biological-E is currently undergoing Phase-3 clinical trials. The vaccine is an RBD protein sub-unit vaccine and is likely to be available in the next few months.
“The proposal of M/s Biological-E was examined and recommended for approval after due diligence by the National Expert Group on Vaccine Administration for Covid-19,” the statement said.
The company has been supported by the government from pre-clinical to third phase study phase. The Department of Biotechnology has provided financial aid of Rs 100 crore given as grant-in-aid to the firm and also partnered with Biological-E to conduct all animal challenge and assay studies through its Research Institute Translational Health Science Technology Institute in Faridabad.
India is expecting a supply of 2 billion doses by the end of December 2021, enough to vaccinate the entire adult population of the country. Government recently said it would be able to give up to 10 million jabs a day by mid-July or early August.
Biological-E’s supply of 300 million is part of the future supply that the government has envisaged.
Health ministry said that the Mission COVID Suraksha- the Indian COVID-19 Vaccine Development is supporting development of 5-6 Covid-19 vaccine candidates some of which are now closer to licensure and introduction in public health systems.
“It has not just accelerated COVID-19 Vaccine development efforts, but also fostered a robust end-to-end vaccine development ecosystem in the country that will be available for other on-going and future research and developmental activities for other vaccines,” the government statement said.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU